Multicenter study of the efficacy of tolvaptan for patients with refractory ascites.
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Sep 2018
Price : $35 *
At a glance
- Drugs Tolvaptan (Primary)
- Indications Ascites
- Focus Therapeutic Use
- 07 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 20 Mar 2014 New trial record